Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer
Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer
复制标题
DOI：
10.1111/j.1349-7006.2006.00203.x
复制
发表时间：
2006-06-01
期刊：
影响因子：
5.7
通讯作者：
Yokozaki, Hiroshi
中科院分区：
文献类型：
--
作者：
Matsukawa, Yasuko;Semba, Shuho;Yokozaki, Hiroshi
Zeste同源物2（EZH 2）蛋白增强子（enhancer of zeste homolog 2，EZH 2）是一种已知的基因转录抑制因子，其过表达与前列腺癌和其他几种癌症的生物学恶性程度有关。本研究旨在探讨EZH 2在胃癌组织中的表达及其与胃癌临床病理特征的关系。检测了13种胃癌细胞系和83例手术切除的人胃癌组织中EZH 2 mRNA和蛋白的表达水平。对83例胃癌组织及相应癌旁胃粘膜进行免疫组化分析，结果显示EZH 2在胃癌组织中的表达高于癌旁胃粘膜，且EZH 2的表达水平与肿瘤大小、浸润深度、血管浸润、淋巴结转移及临床分期密切相关。Kaplan-Meier法计算生存率的单因素分析显示，EZH 2高表达的胃癌患者的预后比EZH 2低表达或不表达的患者差（P = 0.0271）。这些结果提示EZH 2的过度表达可能参与了胃癌的发生和发展，因此EZH 2表达的免疫组化研究可能成为预测胃癌预后的一个新的生物标志物。
Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers. The purpose of this study was to examine the expression of EZH2 and analyze its relationship with the clinicopathological features of human gastric cancers. Expression levels of EZH2 mRNA and protein were examined in 13 gastric cancer cell lines and in 83 surgically removed human gastric cancer tissues. Immunohistochemical analysis of the 83 tissue samples and corresponding non-cancerous gastric mucosa showed that EZH2 was more highly expressed in the cancerous than in the non-cancerous tissues, and the expression levels of EZH2 were highly correlated with tumor size, depth of invasion, vessel invasion, lymph node metastasis and clinical stages. Univariate analysis of survival rate calculated by the Kaplan-Meier method revealed that gastric cancer patients with high-level EZH2 expression had poorer prognosis than those expressing no or low levels of EZH2 (P = 0.0271). These findings suggest that overexpression of EZH2 may contribute to the progression and oncogenesis of human gastric cancers, and thus immunohistochemical study of EZH2 expression may serve as a new biomarker for predicting the prognosis of gastric cancers.